Gut microbiota and Parkinson’s disease DOI Creative Commons
Lin Wang, Ying Cui,

Bingyu Han

et al.

Chinese Medical Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

Abstract Emerging evidence suggests that dysbiosis of the gut microbiota is associated with pathogenesis Parkinson’s disease (PD), a prevalent neurodegenerative disorder. The microbiota–gut–brain axis plays crucial role in development and progression PD, numerous studies have demonstrated potential therapeutic benefits modulations intestinal microbiota. This review provides insights into characterization patients PD highlights associations clinical symptoms underlying mechanisms. discussion underscores increased influence PD. While relationship not fully elucidated, existing research demonstrates strong correlation between changes composition development, further investigation warranted to explain specific

Language: Английский

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases DOI Creative Commons
Jian Sheng Loh, Wen Qi Mak, Li Tan

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Feb. 16, 2024

Abstract The human gastrointestinal tract is populated with a diverse microbial community. vast genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every aspect biology, including health maintenance, development, aging, disease. advent new sequencing technologies culture-independent methods has allowed researchers to move beyond correlative studies toward mechanistic explorations shed light on microbiome–host interactions. Evidence unveiled bidirectional communication between central nervous system, referred as “microbiota–gut–brain axis”. microbiota–gut–brain axis represents an important regulator glial functions, making it actionable target ameliorate development progression neurodegenerative diseases. In this review, we discuss mechanisms As provides essential cues microglia, astrocytes, oligodendrocytes, examine communications microbiota these cells during healthy states Subsequently, diseases using metabolite-centric approach, while also examining role microbiota-related neurotransmitters hormones. Next, targeting intestinal barrier, blood–brain meninges, peripheral immune system counteract dysfunction neurodegeneration. Finally, conclude by assessing pre-clinical clinical evidence probiotics, prebiotics, fecal transplantation A thorough comprehension will foster effective therapeutic interventions for management

Language: Английский

Citations

237
The gut microbiota–brain axis in neurological disorders DOI Creative Commons

Mingming You,

Nan Chen,

Yuanyuan Yang

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(8)

Published: July 20, 2024

Abstract Previous studies have shown a bidirectional communication between human gut microbiota and the brain, known as microbiota–gut–brain axis (MGBA). The MGBA influences host's nervous system development, emotional regulation, cognitive function through neurotransmitters, immune modulation, metabolic pathways. Factors like diet, lifestyle, genetics, environment shape composition together. Most research explored how regulates host physiology its potential in preventing treating neurological disorders. However, individual heterogeneity of microbiota, strains playing dominant role diseases, interactions these microbial metabolites with central/peripheral systems still need exploration. This review summarizes driving neurodevelopmental disorders (autism spectrum disorder attention deficit/hyperactivity disorder), neurodegenerative diseases (Alzheimer's Parkinson's disease), mood (anxiety depression) recent years discusses current clinical preclinical microbe‐based interventions, including dietary intervention, probiotics, prebiotics, fecal transplantation. It also puts forward insufficient on provides framework for further

Language: Английский

Citations

15
Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review DOI Creative Commons

A. Mincic,

Miklós Antal, Lorena Filip

et al.

Clinical Nutrition, Journal Year: 2024, Volume and Issue: 43(7), P. 1832 - 1849

Published: May 31, 2024

Language: Английский

Citations

10
Can microbiota gut-brain axis reverse neurodegenerative disorders in human? DOI
Xingxing Yuan, Serge Yannick Ouédraogo,

Modou Lamin Jammeh

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102664 - 102664

Published: Jan. 1, 2025

Language: Английский

Citations

1
Gut Microbiota-Based Interventions for Parkinson’s Disease: Neuroprotective Mechanisms and Current Perspective DOI
Deepak Kumar, Mahendra Bishnoi, Kanthi Kiran Kondepudi

et al.

Probiotics and Antimicrobial Proteins, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Language: Английский

Citations

1
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease DOI Creative Commons
Yi Zhang, Chengjun Mo,

Penghui Ai

et al.

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 28, 2025

Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, growing body evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert substantial on function composition microbiota. Pharmacomicrobiomics, an emerging field focusing interplay provides potential foundation for making certain advances in personalized medicine. Understanding communication between antiparkinsonian is critical precise treatment Parkinson's disease. Here, we provide historical overview drugs. Moreover, discuss mechanistic insights into complex associations metabolism. addition, draw attention to microbiota-based biomarkers predicting efficacy examine current state-of-the-art knowledge strategies optimize therapy

Language: Английский

Citations

1
The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications DOI Creative Commons
Elisa Menozzi, Anthony H.V. Schapira

CNS Drugs, Journal Year: 2024, Volume and Issue: 38(5), P. 315 - 331

Published: April 3, 2024

The concept of a 'microbiota-gut-brain axis' has recently emerged as an important player in the pathophysiology Parkinson disease (PD), not least because reciprocal interaction between gut bacteria and medications. microbiota can influence levodopa kinetics, conversely, drugs administered for PD composition. Through two-step enzymatic pathway, microbes decarboxylate to dopamine small intestine then dehydroxylate it m-tyramine, thus reducing availability. Inhibition bacterial decarboxylation pathways could therefore represent strategy increase absorption. Other perturbations common PD, such intestinal overgrowth Helicobacter pylori infection, also modulate metabolism, eradication therapies may improve Interventions targeting offer novel opportunity manage disabling motor complications dopa-unresponsive symptoms. Mediterranean diet-induced changes composition might range non-motor Prebiotics levels short-chain fatty acid-producing decrease pro-inflammatory species, with positive effects on clinical symptoms kinetics. Different formulations probiotics showed beneficial outcomes constipation, some them improving levels; however, most effective dosage duration long-term these treatments remain unknown. Data from faecal transplantation studies are preliminary, but show encouraging trends towards improvement both outcomes.This article summarises up-to-date knowledge pharmacomicrobiomics discusses how manipulation represents potential new therapeutic avenue PD.

Language: Английский

Citations

8
Efficacy of probiotic supplements on Parkinson's disease: A systematic review and meta-analysis DOI Creative Commons

Xiaxia Jin,

Wendi Dong,

Kaile Chang

et al.

Complementary Therapies in Medicine, Journal Year: 2024, Volume and Issue: 82, P. 103045 - 103045

Published: May 4, 2024

This study aimed to evaluate the clinical efficacy and safety of probiotics supplementation in treatment Parkinson's disease (PD). We searched China National Knowledge Infrastructure (CNKI), Weipu (VIP) database, Wanfang Database, Sinomed (CBM), PubMed, Embase, Cochrane library Web Science databases for eligible studies from inception January 4th, 2024. Randomized controlled trials (RCTS) comparing effects probiotic supplements placebo patients with PD. Meta-analysis was conducted software Review Manager 5.4. The quality assessment performed according risk bias tool. A total 11 RCTs 756 PD were included this study. found that could increase number complete bowel movements (CBMs) per week improved scores Patient Assessment Constipation Quality Life Questionnaire (PAC-QOL) (SMD = 0.73, 95% CI: 0.54 - 0.92, P < 0.00001, I2 45%; SMD -0.79, -1.19 -0.39, 0.001, 55%, respectively) compared group. However, there no significant difference between two groups improving fecal traits defecation efforts 0.87, 0.01 1.74, 0.05, 94%; 1.24, -1.58 4.06, > 98%, respectively). In terms composite scale scores: after treatment, Movement Disorder Society-Unified-Parkinson Disease Rating Scale Ⅲ score (MDS-UPDRSⅢ) group -0.09, -0.35 0.16, 0%). conclusion, based on overall results available studies, our suggested potential value constipation symptoms patients. Therefore, may be one adjuvant therapy PD-related findings provide more proof supporting effectiveness probiotics, encouraging utilized alone or combination other therapies practice well-designed large sample sizes are required.

Language: Английский

Citations

6
A neurotherapeutic approach with Lacticaseibacillus rhamnosus E9 on gut microbiota and intestinal barrier in MPTP-induced mouse model of Parkinson’s disease DOI Creative Commons
Büşra Aktaş, Belma Aslım, Deniz Ateş

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 4, 2024

Abstract The gut microbiota plays a crucial role in neural development and progression of disorders like Parkinson’s disease (PD). Probiotics have been suggested to impact neurodegenerative diseases via gut-brain axis. This study aims investigate the therapeutic potential Lacticaseibacillus rhamnosus E9, high exopolysaccharide producer, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced mouse model PD. C57BL/6 mice subjected MPTP were fed L. E9 for fifteen days sacrificed after last administration. Motor functions determined by open-field, catalepsy, wire-hanging tests. ileum brain tissues collected ELISA, qPCR, immunohistochemistry analyses. cecum content was obtained analysis. supplementation alleviated MPTP-induced motor dysfunctions accompanied decreased levels striatal TH dopamine. also reduced level ROS striatum DAT expression while increasing DR1. Furthermore, improved intestinal integrity enhancing ZO-1 Occludin reversed dysbiosis induced MPTP. In conclusion, deficits damage as well barrier modulating PD mice. These findings suggest that holds managing through

Language: Английский

Citations

6
The Role of Microbial Metabolites in the Progression of Neurodegenerative Diseases—Therapeutic Approaches: A Comprehensive Review DOI Open Access

Jorge Missiego-Beltrán,

Ana Isabel Beltrán-Velasco

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10041 - 10041

Published: Sept. 18, 2024

The objective of this review is to provide a comprehensive examination the role microbial metabolites in progression neurodegenerative diseases, as well investigate potential therapeutic interventions targeting microbiota. A literature search was conducted across following databases: PubMed, Scopus, Web Science, ScienceDirect, and Wiley. Key terms related gut microbiota, metabolites, specific metabolic products were used. included both preclinical clinical research articles published between 2000 2024. Short-chain fatty acids have been demonstrated play crucial modulating neuroinflammation, preserving integrity blood–brain barrier, influencing neuronal plasticity protection. Furthermore, amino their derivatives exert significant influence on CNS function. These impact health by regulating intestinal permeability, immune responses, directly neuroinflammation oxidative stress, which are integral diseases. Therapeutic strategies, including prebiotics, probiotics, dietary modifications, fecal microbiota transplantation confirmed restore balance enhance production neuroprotective metabolites. novel drug developments based present promising avenues. its represent field with advance our understanding develop treatments for

Language: Английский

Citations

6